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Purpose: Satraplatin is a third generation oral platinum, which has demonstrated antitu-
mor activity. The aim of this phase I study was to determine the maximum tolerated dose
(MTD) of the combination of satraplatin and gemcitabine in patients previously treated
with chemotherapy and in patients without prior chemotherapy. Patients and Methods:
Two separate MTDs were planned in two different patient groups (those with and with-
out prior chemotherapy treatment). Dose escalations were planned in cohorts of three
patients.Tumor measurements were obtained every two cycles. Assessment of response
was performed according to Response Evaluation Criteria in Solid Tumors (RECIST criteria
v.1.0). Results: Thirty subjects were enrolled. A MTD of gemcitabine 1000 mg/m2 days
1 and 8 plus satraplatin 60 mg/m2 days 1–3, every 21 days was determined in the prior
chemotherapy group. No MTD could be determined for the no prior chemotherapy group
treatedwith this schedule. Five patients completed 12 treatment cycles; 22 serious adverse
events (SAE)were observed. Although not an entry criteria, overall conﬁrmed responsewas
observed in 17 (24%) evaluable patients (complete response, CR = 1 and partial response,
PR = 3) and in 3/7 (43%) patients with measure prostate cancer lesions. Conclusions: In
this phase Ib study, the combination of satraplatin and gemcitabine demonstrated to be
safe and efﬁcacious in particular in patients with prostate cancer.
Keywords: satraplatin, oral platinum, phase I study, prostate cancer, solid tumors, chemotherapy
INTRODUCTION
Satraplatin is a third generation oral platinum complex that
has demonstrated activity against several platinum-sensitive
and -resistant human tumor cell lines (Twentyman et al., 1992;
Kelland et al., 1993; Mellish et al., 1993; Orr et al., 1994; Raynaud
et al., 1996).
Preclinical and clinical studies have shown that satraplatin can
potentiate the effects of radiotherapy (Van de Vaart et al., 1997;
Amorino et al., 1999, 2000; George et al., 2001). In clinical stud-
ies, the most frequent dose limiting toxicity (DLT) observed with
satraplatin was myelosuppression (leucopenia and thrombocy-
topenia; McKeage et al., 1995, 1997; Beale et al., 1998; Fokkema
et al., 1999; Kurata et al., 2000; George et al., 2001). Of impor-
tance, no signiﬁcant nephrotoxicity or neurotoxicity was reported
with satraplatin in either preclinical or clinical studies (McKeage
et al., 1993, 1994, 1995, 1997; Beale et al., 1998; Sessa et al., 1998;
Fokkema et al., 2000; Vouillamoz-Lorenz et al., 2003; Ricart et al.,
2009; Galsky et al., 2012).
In phase II trials, single-agent satraplatin demonstrated activity
in patients with small cell lung cancer (SCLC), relapsed ovarian
cancer, and prostate cancer (Judson et al., 1997).
In a phase II trial of satraplatin in 39 chemo-naive patients
with progressive castration-resistant prostate cancer (CRPC), 7
of 22 (32%) patients had a PSA response, toxicity was mainly
hematologic, with grade 3/4 non-hematologic toxicities including
transient increases in aspartate transaminase and bilirubin (Latif
et al., 2005). These results led the European Organization for Can-
cer Research (EORTC) to initiate a phase III trial of satraplatin
plus prednisone vs prednisone alone for ﬁrst-line treatment of
patients with CRPC (Sternberg et al., 2005). Although the target
accrual was 380 patients, only 50 patients were enrolled when
the study was terminated early due to a company decision. This
trial demonstrated that the combination of satraplatin and pred-
nisone resulted in a signiﬁcant increase in PSA response compared
to prednisone alone (33 vs 9%; P = 0.046), and improvement
in progression-free survival (PFS; 5.2 vs 2.5 months; P = 0.023;
Sternberg et al., 2005).
Encouraging results of this EORTC trial led to development
of the SPARC (Satraplatin and Prednisone against Refractory
Cancer) study (Sternberg et al., 2009). This trial was a phase III
randomized double-blind study in which satraplatin plus pred-
nisone was compared to placebo plus prednisone as second-line
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treatment in patients with CRPC who had received one prior
line of cytotoxic chemotherapy. The PFS was 11.1 weeks on the
satraplatin and prednisone arm and 9.7 weeks on the placebo
and prednisone arm (P < 0.001). The median time to pain
progression was 66.1 weeks for satraplatin and 22.3 weeks for
placebo. A PSA response was observed in 25.4 and 12.4% of
patients, respectively (P < 0.001). Despite the improvement in
PFS and the palliative effects in favor of satraplatin, overall survival
(14.3 months in both arms), the preferred endpoint for regula-
tory approval by the FDA, for prostate cancer clinical trials as
most patients have inevaluable bone disease, was not extended by
satraplatin.
Gemcitabine is frequently used in the treatment of several
tumor types including: breast, bladder, non-SCLC, and pancreatic
cancers. Activity has also been reported in biliary tract, cervical,
gall bladder, and ovarian cancers. Gemcitabine has been combined
with several different chemotherapeutic agents and has shown
activity with platinums, taxanes, anthracyclines, 5-ﬂuorouracil,
irinotecan, vinorelbine, and others (Pollera et al., 1994; Glimelius
et al., 1996; Burris et al., 1997; Sternberg, 2000).
The rationale for this study was based primarily upon the
general synergy between platinum compounds and gemcitabine.
Simultaneous drug combination of satraplatin and gemcitabine
in UM-UC-3 cells was often more effective than the individ-
ual drug treatments but overall showed less than additive effects
(GPC Biotech AG, 2005). In this dose ﬁnding study the maximum
tolerated dose (MTD) of the combination of satraplatin and gem-
citabine was evaluated. The hope was to subsequently explore the
combination in a variety of solid tumors.
PATIENTS AND METHODS
PATIENT SELECTION CRITERIA
Eligibility criteria included histological diagnosis of metastatic
or advanced-stage malignant solid tumors that had progressed
following standard therapy or in whom no standard effective
treatment was available. Subjects may have received up to two
prior lines of chemotherapy for their metastatic disease. Patients
with prior therapy with a platinum agent or gemcitabine were
allowed as long as they obtained objective response to one of
these agents and their relapse occurred after 6 months. Other
criteria included: age ≥18 years, ECOG performance status (PS)
0–2, adequate bone marrow function, adequate renal and hep-
atic function, measurable or non-measurable disease according
to Response Evaluation Criteria in Solid Tumors (RECIST crite-
ria v.1.0).
An independent ethical committee at San Camillo and For-
lanini Hospitals approved the protocol. All patients signed written
informed consent according to ICHGoodClinical Practice prior to
study entry. The trial was conducted according to the Declaration
of Helsinki and its amendments.
TRIAL DESIGN AND PROCEDURES
The studywas conducted as a single-center, open label, dose escala-
tion study combining gemcitabinewith satraplatin in subjectswith
advanced solid tumors. Patients were stratiﬁed into two groups at
registration according to the number of lines of prior chemother-
apy (0 vs 1–2). Two separate MTDs were planned for patients with
and without previous chemotherapy. The recommended phase II
dose was deﬁned as the same dose level as the MTD.
Initially, gemcitabine was given by IV infusion on days 1, 8, and
15 every 28 days followed by satraplatin p.o. for the ﬁrst 5 days of
each cycle (every 28-day schedule, part 1). Seventeen patients were
enrolled and treated according to this 28-day schedule. Due to the
increasingly common practice of giving gemcitabine and cisplatin
on an every 3-week schedule and thrombocytopenia encountered
with gemcitabine on the 28-day schedule, the protocol was subse-
quently amended to an every 21-day schedule (part 2). The second
part of the study included 13 additional patients.
At screening and prior to each gemcitabine infusion, medical
history, concomitant medication and PS were recorded. Adverse
events were monitored throughout the trial. In both schedules
patients were to receive up to 12 cycles. Treatment was discon-
tinued after a dose delay of more than 3 weeks, need for more
than one dose reduction, creatinine clearance below 40 ml/min,
documented disease progression, or initiation of confounding
anti-cancer therapy.
DOSE ESCALATION
The starting dose and dose escalation of gemcitabine and
satraplatin in patients with prior chemotherapy and patients
with no prior chemotherapy in parts 1 and 2 of the study are
summarized in Tables 1 and 2.
Dose escalations were planned in cohorts of three patients. If
none of the three patients experienced a DLT during the ﬁrst cycle,
the next three patients were treated at a higher dose level. If any
of the three patients experienced a DLT, three additional patients
were treated at the same dose. If any of the six patients experienced
Table 1 | Dose escalation in part 1 study (every 28-day schedule).
Dose level Gemcitabine mg/m2 days
1, 8, and 15*
Patients with prior chemotherapy Patients with no prior chemotherapy
Satraplatin mg/m2/day given daily for 5 days Satraplatin mg/m2/day given daily for 5 days
Starting 800 40 60
+1 1000 40 60
+2 1000 60 80
+3 1000 80 100
*Cycles are to be repeated every 28 days.
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Table 2 | Dose escalation in part 2 study (every 21-day schedule).
Dose level Gemcitabine mg/m2 days
1 and 8*
Patients with prior chemotherapy Patients with no prior chemotherapy
Satraplatin mg/m2/day given daily for 3 days Satraplatin mg/m2/day given daily for 3 days
Starting 1000 60 80
+1 1000 80 100
+2 1000 100 120
+3 1250 100 120
*Cycles are to be repeated every 21 days.
a DLT, the MTD was exceeded and three additional patients had to
be treated at the lower dose (if only three patients were previously
treated at that dose). The MTD was deﬁned as the dose level at
which 0/6 or 1/6 patients experience DLTs with the next higher
dose having at least 2/3 or 2/6 patients experiencing a DLT.
Toxicities were graded on the basis of Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 3.0. A DLT was
deﬁned as a drug-related CTCAE G3 or G4 non-hematologic tox-
icity (except reversible emesis or diarrhea) or G4 neutropenia
of more than 7 days and/or complicated by infection or G3–
G4 thrombocytopenia or any bleeding episode requiring platelet
transfusion, or delayed recovery (to G1 or baseline, except alope-
cia). A toxicity related to the combination treatmentwhich delayed
initiation of the next cycle by more than 2 weeks was also
a DLT.
SAFETY ASSESSMENT
Safety was assessed weekly by physical examination, vital signs
and laboratory measurements. Subjects were followed for adverse
events for at least 30 days after the last dose of therapy. All study-
related adverse events were followed to resolution or stabilization.
TUMOR ASSESSMENTS
Subjects with measurable disease who had completed at least two
cycles of study treatment and had at least one disease assessment
following the initiation of study treatment were considered evalu-
able for disease response. Tumor measurements were obtained
every two cycles of treatment. Response was assessed according
to RECIST criteria v.1.0 (Therasse et al., 2000). Subjects who dis-
continued for toxicity or after completion of 12 cycles without
disease progression were followed every 3 months up to 1 year
or until progressive disease, subsequent anti-tumor treatment, or
death.
STATISTICAL METHODS
The statistical analysis was only descriptive.
RESULTS
PATIENT CHARACTERISTICS
Thirty patients were entered onto the study. Of these, 17 were
in part 1 (every 28-day schedule) and 13 in part 2 (every 21-day
schedule). Patient characteristics of both groups are described in
Table 3.
TREATMENT, MTD, AND DLTs
The median number of cycles administered was 3. Five patients
completed a total of 12 treatment courses, the maximum number
of cycles per protocol. Details are reported in Table 4.
Every 28-day schedule part I of the trial
The trial was initiated with a 28-day schedule. The starting dose of
satraplatin was 40 mg/m2 in pretreated and 60 mg/m2 in chemo-
naive patients (equivalent to 40 and 60% of the MTD of single-
agent satraplatin).
In the “previous chemotherapy” group, three patients were
treated at the starting dose (gemcitabine 800 mg/m2 days 1, 8, and
15 plus satraplatin 40 mg/m2 days 1–5; every 28 days). A DLT (G3
transaminases)was observed and the cohortwas expanded to three
more patients. Another DLT (G3 transaminases) was observed in
this cohort. Thus, no patients were treated at the next dose level.
Since two DLTs occurred, no MTD could be determined.
In the “no previous chemotherapy” group, eight patients were
treated at the starting dose (gemcitabine 800 mg/m2 days 1, 8,
and 15 plus satraplatin 60 mg/m2 days 1–5; every 28 days). Two
patients were not evaluable for the MTD and were replaced. Both
patients did not receive treatment on days 8 and 15 of cycle 1,
due to G3 thrombocytopenia or withdrawal of consent during
cycle 1. One DLT (G3 diarrhea) was observed in one of the six
evaluable patients. Therefore, three additional patients received
+1 dose level (gemcitabine 1000 mg/m2 days 1, 8, and 15 plus
satraplatin 60 mg/m2 days 1–5; every 28 days). At dose level +1,
one DLT (G3 thrombocytopenia) was observed in one of three
patients. The starting dose (level 0) was therefore determined as
the MTD.
In the “previous chemotherapy” group, no MTD was deter-
mined, and in the “no previous chemotherapy” group, the MTD
was determined at dose level 0. Only 6 of 17 patients received gem-
citabine on D8 and D15. Therefore, the protocol was amended in
both groups to a more convenient every 3-week schedule.
Every 21-day schedule part II of the trial
In the“previous chemotherapy”group, seven patients were treated
at the starting dose (gemcitabine 1000 mg/m2 days 1 and 8 plus
satraplatin 60 mg/m2 days 1–3; every 21 days). One patient was
not evaluable for the MTD, as he received no treatment on day 8
due to urinary infection. One DLT (G3 thrombocytopenia) was
observed in one of six evaluable patients.
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Table 3 | Patients characteristic.
Characteristics All patients Part 1 Part 2
No previous
chemotherapy
Previous
chemotherapy
No previous
chemotherapy
Previous
chemotherapy
N. of patients 30 11 6 2 11
Gender
Male 25 8 5 2 10
Female 5 3 1 0 1
Age (year)
Median 68 68 63 61 67
Range 36–81 40–81 36–74 49–73 59–77
PS
0 8 2 2 1 3
1 19 8 3 0 8
2 3 1 1 1 0
N. of previous chemotherapy regimens
0 13 11 0 2 0
1 11 0 4 0 7
2 6 0 2 0 4
Time since diagnosis (months)
Median 16.7 3.7 26.9 8 78.5
Range 0.1–133.7 0.2–45.4 7.9–107.9 0.1–15.8 12.1–133.8
Tumor type
Prostate 13 0 3 0 10
Pancreatic 6 4 0 1 1
Hepatocellular carcinoma 4 3 1 0 0
Gastric cancer 2 1 0 1 0
Papillary renal carcinoma 1 1 0 0 0
Unknown primary site 1 1 0 0 0
Biliary tract 1 1 0 0 0
Thymic 1 0 1 0 0
Bladder 1 0 1 0 0
Target lesions
Yes/no 23/7 9/2 5/1 2/0 7/4
Median 2 3 2 3 1
Range 0–8 0–6 0–8 1–5 0–5
In the next three patients, the dose was escalated to dose
level +1 (gemcitabine 1000 mg/m2 days 1 and 8 plus satraplatin
80 mg/m2 days 1–3; every 21 days). Two DLTs were observed (G3
thrombocytopenia).
The starting dose (level 0) was, therefore, determined as
the MTD and further enrolment of six patients was planned.
This was stopped after the ﬁrst patient exhibited a DLT (G3
thrombocytopenia) due to a decision of the sponsor.
In the “no previous chemotherapy” group, two patients were
treated at the starting dose (gemcitabine 1000 mg/m2 days 1 and
8 plus satraplatin 80 mg/m2 days 1–3; every 21 days). In each
patient, one DLT was observed (G3 neutropenia and G3 throm-
bocytopenia). Dose level 0 was closed and the MTD could not be
determined.
Safety results
All 30 patients received at least one dose of study treatment. A total
of 137 cycles were evaluated for safety and 310 non-serious adverse
drug reactions (ADRs) were recorded. Eighteen patients experi-
enced 30 SAEs including 22 that were considered“possibly related”
to study treatment. The reported serious ADRs were: diarrhea (1),
rectal hemorrhage (1), ALT increase (3), low hemoglobin (4), low
Frontiers in Oncology | Genitourinary Oncology November 2012 | Volume 2 | Article 175 | 4
“fonc-02-00175” — 2012/11/22 — 12:01 — page 5 — #5
Donato Di Paola et al. Satraplatin and gemcitabine in advanced solid tumors
Table 4 |Treatment (cycles administered).
N. of cycles
administered
All patients Part 1 Part 2
No previous
chemotherapy
Previous
chemotherapy
No previous
chemotherapy
Previous
chemotherapy
Total 137 38 25 4 70
Median 3 2 2 2 6
Range 1–12 1–12 2–12 1–3 2–12
12 cycles 5 1 1 0 3
platelets (8), neutropenia (2), elevated bilirubin (1), and deep
venous thrombosis (1). G4 toxicities occurred in seven patients
(three neutropenia, two anemia, one thrombocytopenia, and one
pain). The predominant adverse event that occurred in greater
than 20% of the patients are reported in Table 5. No major differ-
ences in adverse events G3–G4 were observed between the subjects
in the two groups with and without prior chemotherapy.
ANTITUMOR ACTIVITY
Seventeen of the 30 patients were evaluable for objective tumor
response. Thirteen patients were excluded from the analysis as
per protocol because seven had no measurable disease (only non-
target lesions) at inclusion, four received less than two cycles
of study treatment and two patients had no further disease
assessments following initiation of the study treatment.
One patient with pancreatic cancer and one target lesion in the
liver showed a complete response (CR) at cycle 2 which was con-
ﬁrmed at cycle 4. Time to progression was 422 days. Three patients
had conﬁrmedpartial response (PR). Sevenhad stable disease (SD)
in whom two had a PR that was not conﬁrmed. Six patients had
progression disease (PD).All three patients who obtained a PRhad
metastatic CRPC. Two patients had target lesions in lymph nodes
and in one the liver. Of the two patients that had an unconﬁrmed
PR, one had metastatic CRPC with target lesions in lymph nodes
and the other had a biliary tract tumor with four target lesions
(two in the liver and two in lymph nodes). The overall response
rate (RR; CR + PR) in all (4/17) evaluable patients was 24%.
DISCUSSION
The purpose of this study was to determine the MTD and DLT
of gemcitabine in combination with satraplatin in two groups
of patients with advanced solid tumors. Since there was strong
evidence of synergism of the combination of the two drugs in
preclinical studies, it was decided to conduct the study in two
groups of patients simultaneously.
The ﬁrst group included patients previously treated with one
or two lines of chemotherapy and for whom no further standard
treatment was available. The second group included patients not
previously treated with chemotherapy and in whom there was no
standard treatment. This group included patients with pancreatic,
gastric, hepatocellular carcinoma, biliary tract, or papillary renal
cell cancers (Table 3).According to the protocol, more patients on
the 28-day schedule at dose level 0 should have been included in
order to verify if this was the recommended dose for phase II trials.
However, taking into account the encouraging evidence of activity
of the combination of the two drugs, as evidenced by a CR in a
patient with pancreatic cancer, one PR in a patient with CRPC and
one unconﬁrmed PR in a patient with biliary tract cancer, and the
Table 5 | Adverse events in ≥20% of patients.
Adverse events N. of patients
with G1
N. of patents
with G2
N. of patents
with G3
N. of patents
with G4
% of patients
with (G1–G4)
Asthenia 6 12 4 0 73
Nausea 8 7 1 0 53
Thrombocytopenia 3 4 7 1 50
Neutropenia 1 3 7 3 47
Anorexia 5 8 1 0 47
Anemia 0 8 2 2 40
Fever 7 4 0 0 37
Diarrhea 3 4 2 0 30
Constipation 9 0 0 0 30
Pain 5 1 0 1 23
Edema 5 1 0 0 20
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fact that only 6 of 17 patients had received gemcitabine on days
8 and 15, the protocol was amended in both groups to a more
feasible schedule (gemcitabine days 1 and 8, plus satraplatin days
1–3; every 21 days).
Unfortunately, the second part of the amended study was
stopped after the FDA ODAC meeting in which satraplatin and
prednisone in the SPARC trial failed to reveal an OS advantage
in patients with CRPC and one prior line of chemotherapy. At
that time only 50% of patients in the SPARC trial had received
prior ﬁrst-line treatment with docetaxel which was becoming the
standard ﬁrst-line chemotherapy.
The main objective of the study was to explore the safety of
the combination of gemcitabine with satraplatin. For this reason,
measurable disease was not required in the study. Of particular
interest was the activity in patients with metastatic CRPC. The
cycle length of 21 days would have provided a practical schedule.
In addition, the efﬁcacy of platinums in prostate cancer has been
noted. An oral platinum compound would have potentially been a
very efﬁcacious alternative to other chemotherapeutic agents (Oh
et al., 2007). There were 13 CRPC patients enrolled, all of them
were included after treatment with docetaxel and prednisone, and
four also received a prior second line of chemotherapy.
Only sevenCRPCpatients had target lesions andwere evaluable
according to the protocol, while six were not evaluable for objec-
tive response. Four were not evaluable due to lack of measurable
target lesions, one received less than two cycles and one was not
re-evaluated. In this subgroup of evaluable patients with measur-
able lesions, the objective RR was 43%. Although the number of
evaluable CRPC patients was limited, the data are reinforced by
the fact that PSA responses >50% according to Prostate Speciﬁc
Antigen Working Group (PSAWG) criteria were also observed in
4/12 (33%) patients.
It is unfortunate that development of satraplatin was halted as
it showed potentially interesting results in this study and other
studies in ovarian cancer, lung cancer and as a radioenhancer for
external beam radiation therapy. In actuality, satraplatin is under
development as a radioenhancer and translational research stud-
ies with biomarkers are supported through a Material Cooperative
Research and DevelopmentAgreement (MCRADA) with the NIH.
CONCLUSION
The arsenal of novel hormonal treatment for patients with CRPC
has radically changed in recent years. Nonetheless, the results
of this trial showed that the combination of gemcitabine and
satraplatin, in particular given in an every 3 week cycle is feasible
and has potential anti-tumor activity.
The results were encouraging, in particular, as second and
third line chemotherapy in patients with CRPC, supported by the
high objective RR of 43%. While the drug combination may be
of interest in CRPC, the study did not prospectively enrolled a
deﬁned cohort of CRPC patients. Although the number of evalu-
able patientswas limited due to study closure, the combinationwas
feasible and patients were able to receive the maximum number of
cycles permitted by the protocol (12 cycles).
In conclusion, the results of this study and the compliance
with an oral platinum agent support the further development of
satraplatin to better quantify its activity and safety in patients with
CRPC after receiving docetaxel and other novel therapies such as
abirateroneor enzalutamide. The combinationwas also interesting
in pancreatic and biliary tumors.
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